RxDoctor Payments Data

Irvin Bonder, MD

Urology · Rockaway, NJNPI 1740257732

Payments from drug & device makers

$5,563in general payments, 2019–2025

Across 250 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$1K
  • Astellas Pharma US Inc$688
  • AbbVie$373
  • Sumitomo Pharma America, Inc.$299
  • Endo Pharmaceuticals Inc.$296
  • Pfizer$279
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$4,36278%
  • Education$2575%
  • Other$94417%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,563 in reported general payments places this provider in the 70th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$170,241
Medicare patients
510
Services billed
2,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron88$83,908
GemtesaVibegron60$64,148
ElmironPentosan Polysulfate Sodium11$18,706
Tamsulosin Hcl825$13,519
Silodosin65$6,857
Potassium Citrate ErPotassium Citrate79$6,102
Testosterone49$6,002
Finasteride330$4,974
Darifenacin ErDarifenacin Hydrobromide18$4,797
Oxybutynin Chloride ErOxybutynin Chloride168$4,753
Solifenacin Succinate107$4,038
Alfuzosin Hcl ErAlfuzosin Hcl130$3,395
Tadalafil12$2,108
Fesoterodine Fumarate ErFesoterodine Fumarate13$1,949
Dutasteride47$1,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$688$83,90888 claims
Sumitomo Pharma America, Inc.Gemtesa$299$64,14860 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 401 urology providers in New Jersey.

Other urology in Rockaway

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →